Vanguard Group Inc. boosted its position in Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) by 13.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,206,436 shares of the biopharmaceutical company’s stock after buying an additional 144,854 shares during the quarter. Vanguard Group Inc. owned 3.64% of Bellicum Pharmaceuticals worth $14,092,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of BLCM. Bank of New York Mellon Corp lifted its holdings in Bellicum Pharmaceuticals by 1.0% in the 1st quarter. Bank of New York Mellon Corp now owns 95,934 shares of the biopharmaceutical company’s stock worth $1,184,000 after buying an additional 935 shares in the last quarter. American International Group Inc. lifted its holdings in Bellicum Pharmaceuticals by 7.1% in the 1st quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 852 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in Bellicum Pharmaceuticals by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 83,338 shares of the biopharmaceutical company’s stock worth $1,029,000 after buying an additional 610 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Bellicum Pharmaceuticals by 17.9% in the 1st quarter. Geode Capital Management LLC now owns 179,012 shares of the biopharmaceutical company’s stock worth $2,209,000 after buying an additional 27,201 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Bellicum Pharmaceuticals by 174.1% in the 1st quarter. Renaissance Technologies LLC now owns 227,200 shares of the biopharmaceutical company’s stock worth $2,804,000 after buying an additional 144,300 shares in the last quarter. Hedge funds and other institutional investors own 54.78% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://theolympiareport.com/2017/11/20/bellicum-pharmaceuticals-inc-blcm-holdings-boosted-by-vanguard-group-inc.html.

A number of brokerages have recently issued reports on BLCM. ValuEngine upgraded shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, September 18th. Raymond James Financial, Inc. set a $18.00 target price on shares of Bellicum Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. Jefferies Group LLC restated a “buy” rating and issued a $16.00 target price on shares of Bellicum Pharmaceuticals in a research note on Thursday, September 14th. BidaskClub lowered shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Finally, Zacks Investment Research upgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $26.20.

Shares of Bellicum Pharmaceuticals, Inc. (NASDAQ BLCM) opened at $10.00 on Monday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.08 and a current ratio of 6.08. Bellicum Pharmaceuticals, Inc. has a 12 month low of $7.41 and a 12 month high of $22.99.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.03. The business had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.03 million. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 77.16%. The company’s revenue for the quarter was up 18.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.66) EPS. equities research analysts forecast that Bellicum Pharmaceuticals, Inc. will post -2.94 EPS for the current year.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Want to see what other hedge funds are holding BLCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM).

Institutional Ownership by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.